Evidence map›Paper›PMID 32770325›Full record

ArticleMolecular and cellular biochemistry2020

Paeonol suppresses the effect of ox-LDL on mice vascular endothelial cells by regulating miR-338-3p/TET2 axis in atherosclerosis.

Yunfu Yu, Rui Yan, Xiaozhen Chen, Tao Sun, Jifeng Yan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Targeted drug delivery systems for atherosclerosis.Journal of nanobiotechnology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yunfu YuDepartment of Cardiology, Central China Fuwai Hospital, Heart Center of Henan Provincial People's Hospital, No. 1 Yuwai Street, Zhengdong New District, Zhengzhou, 450000, Henan Province, China.
Rui YanDepartment of Cardiology, Central China Fuwai Hospital, Heart Center of Henan Provincial People's Hospital, No. 1 Yuwai Street, Zhengdong New District, Zhengzhou, 450000, Henan Province, China.
Xiaozhen ChenDepartment of Cardiology, Central China Fuwai Hospital, Heart Center of Henan Provincial People's Hospital, No. 1 Yuwai Street, Zhengdong New District, Zhengzhou, 450000, Henan Province, China.
Tao SunDepartment of Cardiology, Central China Fuwai Hospital, Heart Center of Henan Provincial People's Hospital, No. 1 Yuwai Street, Zhengdong New District, Zhengzhou, 450000, Henan Province, China.
Jifeng YanDepartment of Cardiology, Central China Fuwai Hospital, Heart Center of Henan Provincial People's Hospital, No. 1 Yuwai Street, Zhengdong New District, Zhengzhou, 450000, Henan Province, China. vidyom@163.com.ORCID http://orcid.org/0000-0003-3085-7737
Henan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherosclerosis is the common vascular disease. Vascular smooth muscle cell proliferation and vascular endothelial cell (VEC) dysfunction are involved in the causes of atherosclerosis. And oxidized low-density lipoprotein (ox-LDL)-induced vascular endothelial cells (VECs) are suitable models for studying atherosclerosis development. Paeonol was reported to repress ox-LDL-induced VEC progression. However, its detailed mechanism was not fully reported. MicroRNAs (miRNAs) acted as regulators in multiple diseases. Previous findings found that microRNA-338-3p (miR-338-3p) was overexpressed in Atherosclerosis process. However, the function and underlying mechanism of miR-338-3p in ox-LDL-treated VECs needed to be elucidated. The purpose of this research was to reveal the role of miR-338-3p in paeonol-regulated ox-LDL-induced VEC progression. Cell counting kit-8 (CCK-8) and flow cytometry were employed to determine cell viability and apoptosis, respectively. Moreover, the levels of IL-6 and IL-1β were analyzed using enzyme-linked immunosorbent assay, as well as the contents of reactive oxygen species, lactate dehydrogenase, and malonic dialdehyde were investigated using related kits. Furthermore, quantitative real-time polymerase chain reaction was carried out to determine the expression of miR-338-3p. Western blot assay was conducted to detect the level of tet methylcytosine dioxygenase 2 (TET2). Besides, the interaction between miR-338-3p and TET2 was predicted by DIANA, and then confirmed by the dual-luciferase reporter assay and RNA immunoprecipitation assay. Ox-LDL repressed mice VEC viability, and promoted apoptosis, inflammatory response, and oxidative injury. Paeonol inhibited the effect of ox-LDL on the growth of the VECs. Furthermore, paeonol regulated VEC development via downregulating miR-338-3p expression. Interestingly, miR-338-3p targeted TET2 and inhibited TET2 expression. MiR-338-3p modulated ox-LDL-treated VEC growth through suppressing TET2 expression. We demonstrated that paeonol attenuated the effect of ox-LDL on the development of mice VECs via modulating miR-338-3p/TET2 axis, providing a theoretical basis for the treatment of AS.

Indexed as

AcetophenonesAnimalsAortaApoptosisAtherosclerosisCell ProliferationCells, CulturedCell SurvivalDioxygenasesDNA-Binding ProteinsEndothelial CellsLipoproteins, LDLMiceMicroRNAsOxidative StressProto-Oncogene ProteinsAcetophenonesDioxygenasesDNA-Binding ProteinsLipoproteins, LDLMicroRNAsMirn338 microRNA, mouseoxidized low density lipoproteinpaeonolProto-Oncogene ProteinsTet2 protein, mouseAtherosclerosismiR-338-3pOx-LDLPaeonolTET2VECs

Identifiers

PMID32770325
OpenAlexW3048302030

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.